FY2025 EPS Estimates for APLS Boosted by Cantor Fitzgerald

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for Apellis Pharmaceuticals in a research note issued on Wednesday, July 2nd. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the company will post earnings per share of ($0.22) for the year, up from their prior estimate of ($2.38). Cantor Fitzgerald has a "Overweight" rating and a $44.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Cantor Fitzgerald also issued estimates for Apellis Pharmaceuticals' FY2026 earnings at ($0.91) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The firm had revenue of $149.90 million during the quarter, compared to analysts' expectations of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The business's revenue for the quarter was down 3.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.54) earnings per share.

Several other research firms also recently issued reports on APLS. Royal Bank Of Canada cut their price target on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Wells Fargo & Company raised their target price on shares of Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an "equal weight" rating in a report on Monday, June 2nd. Bank of America downgraded shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the company from $41.00 to $23.00 in a report on Friday, May 9th. Morgan Stanley increased their price target on shares of Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an "equal weight" rating in a research report on Wednesday. Finally, Needham & Company LLC cut their price objective on Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $39.79.

Apellis Pharmaceuticals Price Performance

APLS traded up $0.17 during trading on Friday, reaching $17.99. 891,120 shares of the stock were exchanged, compared to its average volume of 2,347,184. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -10.05 and a beta of 0.67. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $42.47. The business's 50 day moving average price is $18.15 and its two-hundred day moving average price is $23.59.

Insider Activity at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $18.77, for a total transaction of $93,850.00. Following the transaction, the general counsel directly owned 133,730 shares in the company, valued at approximately $2,510,112.10. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in APLS. EverSource Wealth Advisors LLC grew its holdings in Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after purchasing an additional 758 shares during the period. Signaturefd LLC boosted its holdings in shares of Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after purchasing an additional 918 shares during the last quarter. Assetmark Inc. grew its stake in shares of Apellis Pharmaceuticals by 3,938.7% during the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company's stock valued at $27,000 after buying an additional 1,221 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at $83,000. Finally, US Bancorp DE increased its holdings in shares of Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after buying an additional 1,327 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).